SQZB Stock Overview A clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
SQZ Biotechnologies Company Competitors Price History & Performance
Summary of share price highs, lows and changes for SQZ Biotechnologies Historical stock prices Current Share Price US$0.025 52 Week High US$0.12 52 Week Low US$0.012 Beta 1.52 1 Month Change -10.71% 3 Month Change -37.50% 1 Year Change 24.07% 3 Year Change -99.75% 5 Year Change n/a Change since IPO -99.81%
Recent News & Updates
SQZ Biotechnologies Files Form 15 Jan 05
SQZ Biotechnologies Company Contemplates Bankruptcy. Nov 10 SQZ Biotechnologies Company Contemplates Bankruptcy. Nov 09
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting Nov 04
SQZ Biotechnologies Company(OTCPK:SQZB) dropped from S&P TMI Index Jul 10
New major risk - Market cap size Jun 28 See more updates
SQZ Biotechnologies Files Form 15 Jan 05
SQZ Biotechnologies Company Contemplates Bankruptcy. Nov 10 SQZ Biotechnologies Company Contemplates Bankruptcy. Nov 09
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting Nov 04
SQZ Biotechnologies Company(OTCPK:SQZB) dropped from S&P TMI Index Jul 10
New major risk - Market cap size Jun 28
SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30% Jun 26
SQZ Biotechnologies Receives Written Notice from the NYSE Regarding Non-Compliance with Section 802.01B of the NYSE Listed Company Manual Jun 16
First quarter 2023 earnings released: US$0.60 loss per share (vs US$0.75 loss in 1Q 2022) May 12
Price target increased by 44% to US$19.00 May 09
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 24
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange Jan 19
We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully Jan 05
SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress Dec 07
High number of new directors Dec 04
Price target decreased to US$15.40 Dec 02 SQZ Biotechnologies Announces Resignation of Micah Zajic as Chief Financial Officer, Effective December 31, 2022
Price target decreased to US$17.67 Nov 16
Third quarter 2022 earnings released: US$0.77 loss per share (vs US$0.80 loss in 3Q 2021) Nov 12
SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting Nov 11
SQZ Biotechnologies GAAP EPS of -$0.77 beats by $0.06, revenue of $3.5M misses by $0.76M Nov 09
SQZ Biotech spikes as H.C. Wainwright initiates with Buy citing platform technology Oct 20
Sqz Biotechnologies Publishes Preclinical Research Demonstrating Sqz® Aac Platform’S Potential as an Effective Red Blood Cell-Derived Immunotherapy Oct 04
SQZ Biotechnologies Company Presents Preclinical SQZ TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies Sep 13
SQZ Biotechnologies Company Announces Leadership Transition Sep 07
Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans? Aug 20
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 05
SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M Aug 04
SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ(R) APCs and Effective CD8 T Cell Activation Jul 13 SQZ Biotechnologies Company Appoints Micah Zajic as Principal Financial Officer
SQZ Biotechnologies names business chief as CFO Jul 11
SQZ Biotechnologies Company(NYSE:SQZ) dropped from Russell 2500 Index Jun 26
Price target decreased to US$25.17 Jun 17
SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs Jun 17
SQZ Biotechnologies Appoints Marshelle Smith Warren as Chief Medical Officer Jun 01
Independent Director recently bought US$50k worth of stock May 28
Price target decreased to US$27.50 May 25
SQZ Biotechnologies Announces Integrated Point-Of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than A More Conventional Clean Room-Based Process May 19
Consensus revenue estimates fall by 14% May 17
Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook May 17
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 11 SQZ Biotechnologies Company Announces First Data Presentation on Non-Clinical Studies of Point-Of-Care Manufacturing System May 06
Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation May 02
SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors Apr 28
Price target decreased to US$30.60 Apr 27
SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo Apr 12
SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes Apr 06
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 18
Price target decreased to US$31.00 Mar 18
SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ Feb 02
SQZ Biotechnologies Company Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV Jan 25
Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation Jan 11
SQZ Biotechnologies Company Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint Hpv+ Solid Tumor Patient Dec 10
SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose Dec 03
SQZ Biotechnologies Company Announces Acceptance by Roche Accelerator in China Dec 02
Third quarter 2021 earnings released: US$0.80 loss per share (vs US$7.03 loss in 3Q 2020) Nov 13
SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform Sep 14
Second quarter 2021 earnings released: US$0.68 loss per share (vs US$6.05 loss in 2Q 2020) Aug 05
Will SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely? Jul 30 SQZ Biotechnologies Company(NYSE:SQZ) dropped from Russell 2500 Growth Index
SQZ Biotechnologies Company Presents Regenerative Medicine Data Demonstrating Neuron Generation from Human Pluripotent Stem Cells with Single Delivery of mRNA Transcription Factor Jun 24
SQZ Biotechnologies Company Tolerizing Antigen Carrier Program Induces Antigen-Specific Immune Tolerance in Preclinical Models Demonstrating Potential for Broad Applicability Across Autoimmune Diseases Jun 10
SQZ Biotechnologies Presents Initial First-In-Human Data Demonstrates Investigational Cell Therapy is Safe and Can Stimulate Immune Responses in Certain Patients with Advanced or Metastatic HPV16+ Tumors Jun 05
SQZ Biotechnologies Company to Present First Clinical Data at the American Society of Clinical Oncology Annual Meeting from Ongoing Phase 1 Study in Patients with Advanced or Metastatic HPV+ Tumors May 21
Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ) May 16
First quarter 2021 earnings released: US$0.59 loss per share (vs US$6.41 loss in 1Q 2020) May 12
SQZ Biotechnologies to Present New Data on Rapid Cell Therapy Manufacturing Capabilities and Advantages in Cell Performance at ASGCT 2021 Apr 29
Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts Mar 25
SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report Mar 20
Full year 2020 earnings released: US$9.35 loss per share (vs US$18.89 loss in FY 2019) Mar 20
SQZ Biotechnologies to Present Preclinical Data on KRAS Tumor Targets and Next Generation SQZ eAPCs Mar 12
New 90-day low: US$22.01 Feb 12
SQZ Biotechnologies Announces FDA Clearance of IND Application to Allow for Clinical Trial with SQZ Activating Antigen Carriers (SQZ AACs) in Patients with HPV+ Tumors Feb 02
We Think SQZ Biotechnologies (NYSE:SQZ) Can Afford To Drive Business Growth Feb 01
SQZ Biotech Presents Preclinical Data for SQZ APC and AAC Cellular Vaccine Platforms at SITC 2020, Including First-Time SQZ APC Combination Preclinical Data Nov 11
SQZ Biotechnologies Company has completed an IPO in the amount of $70.58824 million. Oct 31 Shareholder Returns SQZB US Biotechs US Market 7D -9.1% -3.6% -2.4% 1Y 24.1% -2.6% 23.4%
See full shareholder returns
Return vs Market: SQZB matched the US Market which returned 23.4% over the past year.
Price Volatility Is SQZB's price volatile compared to industry and market? SQZB volatility SQZB Average Weekly Movement 15.8% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: SQZB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SQZB's weekly volatility has decreased from 49% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents.
Show more SQZ Biotechnologies Company Fundamentals Summary How do SQZ Biotechnologies's earnings and revenue compare to its market cap? SQZB fundamental statistics Market cap US$737.28k Earnings (TTM ) -US$71.64m Revenue (TTM ) US$12.12m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SQZB income statement (TTM ) Revenue US$12.12m Cost of Revenue US$51.79m Gross Profit -US$39.67m Other Expenses US$31.97m Earnings -US$71.64m
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) -2.43 Gross Margin -327.29% Net Profit Margin -591.07% Debt/Equity Ratio 0%
How did SQZB perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 04:31 End of Day Share Price 2024/12/20 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources SQZ Biotechnologies Company is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Tazeen Ahmad BofA Global Research Leah Rush Cann Brookline Capital Markets Thomas Shrader BTIG
Show 4 more analysts 
